Details for Patent: 8,415,355

Which drugs does patent 8,415,355 protect, and when does it expire?

Patent 8,415,355 protects KISQALI and KISQALI FEMARA CO-PACK (COPACKAGED) and is included in two NDAs.

This patent has sixty patent family members in forty-seven countries.

Summary for Patent: 8,415,355

Title:	Pyrrolopyrimidine compounds and their uses
Abstract:	The present invention relates to compounds of formula (I) and to pharmaceutically acceptable salts and pharmaceutical compositions thereof. The present invention also relates to use of the compounds of formula (I) in modulating the activity of protein kinases and in the treatment of disease, particularly a disease, disorder or syndrome associated with CDK 4 inhibition. ##STR00001##
Inventor(s):	Brain; Christopher Thomas (Cambridge, MA), Sung; Moo Je (Cambridge, MA), Lagu; Bharat (Acton, MA)
Assignee:	Novartis AG (Basel, CH) Astex Therapeutics Ltd. (Cambridge, GB)
Application Number:	12/545,322
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,415,355
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,415,355

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	KISQALI	ribociclib succinate	TABLET;ORAL	209092-001	Mar 13, 2017		RX	Yes	Yes			Y	Y
Novartis	KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate	TABLET;ORAL	209935-001	May 4, 2017		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,415,355

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	073116
Argentina	111763
Australia	2009284098
Brazil	PI0917791
Canada	2734802
Chile	2011000306
China	102186856